Partner Kathleen Sanzo is featured in a Pink Sheet article reporting that some sponsor meetings with US Food and Drug Administration (FDA) staff will resume later this month in a hybrid format, and if all runs smoothly, could switch to in-person by the end of 2023.
Kathleen noted that the change is "better than nothing," but worried the industry may not be able to have all those who worked on a drug development application be present in the room.
Read the full Pink Sheet article >>
Subscription may be required.